Recherches et rapports en sciences médicales

Serum Firmness and Cost Value aimed at COVID−19

Abstract

Anshula Chawla

The first vaccine vial was developed a few centuries ago, and it has resulted in a significant reduction in infectious disease morbidity and mortality. According to the World Health Organization (WHO), the discovery of the novel SARS-CoV-2 virus and the COVID-19 disease, as well as its steady progression to a global pandemic with confirmed cases and reported deaths, was extremely catastrophic. This resulted in an unexpected need for preventative and cost-effective measures to mitigate the virus's devastating impact, followed by accelerated competition among pharmaceutical behemoths to manufacture and dispense vaccines at an exponential rate. Non-pharmaceutical medications, such as mandated face mask policies, travel restrictions, and widespread disinfectant use, were somewhat effective in mitigating the catastrophic effect.